[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

@ScorpionFund Scorpion Capital

Scorpion Capital posts on X about $slno, tokyo, market cap, reduce the most. They currently have XXXXXX followers and X posts still getting attention that total XXX engagements in the last XX hours.

Engagements: XXX #

• X Week XXXXX +420%
• X Month XXXXX -XX%
• X Months XXXXXXX -XX%
• X Year XXXXXXXXX -XX%

Mentions: X #

• X Week X -XX%
• X Month X -XX%
• X Months XX +21%
• X Year XX +65%

Followers: XXXXXX #

• X Week XXXXXX -XXXX%
• X Month XXXXXX -XXXX%
• X Months XXXXXX +0.11%
• X Year XXXXXX -XXXX%

CreatorRank: XXXXXXXXX #

Social Influence

Social category influence travel destinations XX% finance XX%

Social topic influence $slno #8, tokyo 25%, market cap 25%, reduce 25%, $6920t 25%, $14b 25%, $100200mm 25%, number of XX%

Top accounts mentioned or mentioned by @jfais20 @bioadvo @joinyellowbrick @threadanddoc @seedy19tron @pharmdca @breakoutpoint

Top assets mentioned Soleno Therapeutics, Inc. Common Stock (SLNO)

Top Social Posts

Top posts by engagements in the last XX hours

"Lasertec $6920 (Tokyo) latest quarter is quite the crash and burn. Consistent with a fraud in the final throes. It's down substantially since our report but still $14B market cap vs. $100-200MM prior to becoming a story stock. Look out below. Where do we start -"We will no longer disclose the quarterlyresultsof orders and order backlog" -"Shareholders and investors have asked us to reduce short term share price volatility by not disclosing orders on a quarterlybasis"; interesting as orders are the main figure investors care about. -Sales fell year over year and sequentially esp equipment"
X Link 2024-10-31T19:34Z 84.8K followers, 20.6K engagements

"1/2 $SLNO Soleno Therapeutics. Our thoughts aheadof earningstoday: X. We don't think this quarter is particularly critical - the rubber meets the road in the next couple of quarters. VYKAT XR became commercially available in April. This quarter just reflects the initial bolus of patients - the new restaurant effect a short-term tailwind given the number of desperate families willing to try anything. Patients and doctors are willing to give any new drug a try for 3-6 months in some cases longer before throwing in the towel. We spoke with enough trial investigators who indicated close to a 100%"
X Link 2025-11-04T20:50Z 84.8K followers, 40.9K engagements

"$SLNO Soleno Therapeutics earnings call was a farce. We've never seen a short report mentioned so many times by mgmt and sell-side. Only scams tend to engage with short reports. Credible companies don't bother. X. The attempt to blame our report for a slowdown in start forms is amusing and disingenuous in the context of a dirty drug that failed its Phase X trial (); not to mention the fatality of a young patient who had recently started the drug. Our report simply documented pre-existing reports of hospitalizations for heart failure in kids who had recently started the drug among various"
X Link 2025-11-05T14:15Z 84.8K followers, 36.6K engagements